Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy
Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy
复制标题
DOI：
10.1515/jbcpp-2020-0468
复制
发表时间：
2021-07-01
影响因子：
--
通讯作者：
Fatmawati, Umi
中科院分区：
文献类型：
--
作者：
Pratama, Novan Yusuf Indra;Zulkarnain, Bambang Subakti;Fatmawati, Umi
目的：本研究旨在评估耐多药结核病（MDR-TB）患者中利奈唑胺诱导的血液学副作用的患病率并分析其危险因素。方法：数据收集自2018年1月至2020年5月期间接受利奈唑胺治疗的MDR-TB患者的病历。结果：93例患者中有27例（29.0%）发生血液学副反应，其中12例（27.0%）发生血液学副反应。最常见的影响是贫血（29.0%），其次是血小板减少（3.2%）和白细胞减少（2.2%）。利奈唑胺治疗2周后报告了这些副作用。多因素分析表明，利奈唑胺剂量大于11 mg/kgBW/d或患者体重小于54 kg是导致贫血的独立危险因素。结论：贫血是耐多药结核患者中最常见的利奈唑胺血液学副作用。因此，可能建议体重低于54 kg且接受利奈唑胺治疗至少2周后的患者进行血红蛋白监测。
Objectives: This study aimed to estimate the prevalence and analyze the risk factors for linezolid-induced hematological side effects in multidrug-resistant tuberculosis (MDR-TB) patients.Methods: Data were collected from medical records of MDR-TB patients who received linezolid between January 2018 and May 2020. Statistical significance analysis and multivariate analysis were performed with SPSS version 24 software.Results: Hematological side effectswere identified in 27 out of 93 patients (29.0%). Themost prevalent effectwas anemia (29.0%), while the less prevalent effects were thrombocytopenia (3.2%) and leukopenia (2.2%). These side effects were reported after 2 weeks of linezolid treatment. The drug dose was more than 11 mg/kgBW/day or patient weighing less than 54 kg was identified as an independent risk factor for anemia in multivariate analysis.Conclusions: Anemia was the most prevalent of linezolidinduced hematological side effects in MDR-TB patients. Therefore, hemoglobin monitoring might be recommended in patients weighing less than 54 kg and after receiving linezolid therapy for at least 2 weeks.